WeTrials
Active, not recruiting

\Multi-Center Phase I Study of Avutometinib (VS-6766), a RAF/MEK Clamp in Combination With Defactinib, a FAK Inhibitor, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway or NF2 Alterations

What is this study?

This study is testing a new medication called avutometinib, combined with another drug called defactinib, to see if it is safe for children and young adults with tough-to-treat solid tumors. Researchers want to find the best dose that shrinks tumors while keeping side effects as mild as possible.

Who can participate?

This trial is for patients aged 3 to 30 years old who have certain types of childhood tumors with specific genetic changes. Participants also need to meet general health and physical ability requirements to join safely.

What will happen?

Participants will receive the study medications and be closely monitored by the medical team to check for safety and effectiveness. Your doctors will carefully track how your body responds to the treatment and watch for any side effects.

Where and when?

The study takes place at medical centers in Atlanta, Georgia, and New York, New York. Currently, the study is active but not actively looking for new participants.

Key Points
  • 1Tests a combination of new anti-cancer drugs for children and young adults.
  • 2Aims to find the safest and most effective dose for hard-to-treat tumors.
  • 3Currently active at specific locations in the United States, though not currently accepting new patients.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Refractory CancerCNS TumorsCNS Tumor, AdultCNS Tumor, ChildhoodMAP Kinase Family Gene MutationNF1Plexiform NeurofibromaLow-grade GliomaOptic Pathway GliomasNeuroblastomaPrimary Brain TumorSolid TumorSolid Tumor, AdultSolid CarcinomaCentral Nervous System Tumor

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.